Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs ProShares Ultra Gold ETF (UGL) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
ProShares Ultra Gold ETFTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs ProShares Ultra Gold ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while ProShares Ultra Gold ETF trades at $52.39. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.

BIOUGL
Market Cap
$9.43B
Sector
HealthLeveraged / Inverse
52-Week High
$356.25$85.62
52-Week Low
$241.71$34.37
Enterprise Value
$9.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

No Aura AI signal available yet.

ProShares Ultra Gold ETF

UGL trades at $50.69, up 4.45% in 24 hours, with a bullish technical signal driven by moving averages. The stock shows strong momentum but faces overbought conditions with a 6-day RSI at 85.76. Recent news highlights gold's rebound potential, with analysts projecting prices toward $4,500–$5,000 per ounce, benefiting gold-related equities.

The outlook for UGL is positive amid supportive gold market dynamics, though high RSI levels suggest near-term consolidation risks. Investment appeal hinges on sustained gold strength, while exposure to commodity volatility and Fed policy shifts remain key watchpoints for shareholders.

Returns comparison

Trailing returns across standard periods

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About ProShares Ultra Gold ETF

UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.

Read more on UGL